View of Cost-effectiveness of abatacept compared to other biological agents for the treatment of moderately to severely active rheumatoid arthritis in patients who failed with methotrexate in Peruvian Social Security during 2010

Return to Article Details Cost-effectiveness of abatacept compared to other biological agents for the treatment of moderately to severely active rheumatoid arthritis in patients who failed with methotrexate in Peruvian Social Security during 2010 Download Download PDF